# Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

> **NCT00622466** · PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00622466
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-23
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study sponsor requested that the study be permanently closed by letter.
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622466, "Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00622466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*